VEGFA and metastatic colorectal cancer: In the treatment of metastatic colorectal cancer, for example, VEGF inhibitors Bevacizumab, an antiangiogenic monoclonal antibody (mAb) approved by the FDA, which can return abnormal tumor structure to a more normal phenotype (Saxton and Sabatini, 2017), Notch 1 signaling (Lee et al., 2015), and D2 receptors-angiopoietin 1 signaling (Chauvet et al., 2017).